[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-338809-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-338809-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","plau-promotes-growth-and-attenuates-cisplatin-chemosensitivity-in-arid1a-depleted-non-small-cell-lung-cancer-through-interaction-with-tm4sf1","PLAU promotes growth and attenuates cisplatin chemosensitivity in ARID1A-depleted non-small cell lung cancer through interaction with TM4SF1","","Loss of ARID1A, a SWI/SNF chromatin remodeling subunit, drives malignant progression across cancers including non-small cell lung cancer (NSCLC). By analyzing three GEO RNA-seq datasets, PLAU emerged as a gene induced upon ARID1A depletion. PLAU overexpression increased NSCLC cell growth, colony formation, cisplatin resistance, and survival under serum deprivation, and enhanced tumorigenesis in nude mice. Mechanistically, PLAU bound TM4SF1 to activate Akt signaling; TM4SF1 knockdown reduced growth, survival, and sensitized cells to cisplatin. Anti-TM4SF1 neutralizing antibody similarly suppressed tumor growth, resistance, and tumorigenesis, supporting TM4SF1 as a therapeutic target.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/plau-promotes-growth-and-attenuates-cisplatin-chemosensitivity-in-arid1a-depleted-non-small-cell-lung-cancer-through-interaction-with-tm4sf1/338809/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/plau-promotes-growth-and-attenuates-cisplatin-chemosensitivity-in-arid1a-depleted-non-small-cell-lung-cancer-through-interaction-with-tm4sf1/338809.png","ImageObject",300,407,{"name":42,"@type":43},"Jiven","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does ARID1A loss influence NSCLC progression and therapy response?","Question",{"text":63,"@type":64},"ARID1A loss contributes to aggressive progression and is associated with drug resistance in NSCLC. The study focuses on identifying downstream genes that mediate these effects.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What role does PLAU play in ARID1A-depleted NSCLC?",{"text":68,"@type":64},"PLAU is induced upon ARID1A depletion. Overexpressing PLAU promotes NSCLC cell growth and colony formation, enhances survival, and increases cisplatin resistance.",{"name":70,"@type":61,"acceptedAnswer":71},"How is the PLAU–TM4SF1–Akt axis connected to chemoresistance?",{"text":72,"@type":64},"PLAU interacts with TM4SF1 to activate Akt signaling. TM4SF1 overexpression mimics PLAU effects, while TM4SF1 knockdown or anti-TM4SF1 antibody reduces growth and cisplatin resistance.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},338809,1790179701,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","Zheng et al. Biology Direct (2024) 19:7 [https://doi.org/10.1186/s13062-024-00452-7](https://doi.org/10.1186/s13062-024-00452-7)  \nBiology Direct  \nRESEARCH Open Access  \nPLAU promotes growth and attenuates  cisplatin chemosensitivity in ARID1A-depleted non-small cell lung cancer through interaction with TM4SF1  \nYuanliang Zheng 1†, Lixiang Zhang 1†, Kangliang Zhang2, Shenghao Wu3, Chichao Wang 1, Risheng Huang 1* and Hongli Liao4*  \nAbstract  \nLoss of ARID1A, a subunit of the SWI/SNF chromatin remodeling complex, contributes to malignant progression in multiple cancers including non-small cell lung cancer (NSCLC) . In the search for key genes mediating the aggressive phenotype caused by ARID1A loss, we analyzed 3 Gene Expression Omnibus (GEO) datasets that contain RNA sequencing data from ARID1A-depleted cancer cells. PLAU was identified as a common gene that was induced in different cancer cells upon ARID1A depletion. Overexpression of PLAU positively modulated NSCLC cell growth, colony formation, cisplatin resistance, and survival under serum deprivation. Moreover, enforced expression of PLAU enhanced tumorigenesis of NSCLC cells in nude mice. Mechanistically, PLAU interacted with TM4SF1 to promote the activation of Akt signaling. TM4SF1-overexpressing NSCLC cells resembled those with PLAU overepxression. Knockdown of TM4SF1 inhibited the growth and survival and increased cisplatin sensitivity in NSCLC cells. The interaction between PLAU and TM4SF1 led to the activation of Akt signaling that endowed ARID1A-depleted NSCLC cells with aggressive properties. In addition, treatment with anti-TM4SF1 neutralizing antibody reduced the growth, cisplatin resistance, and tumorigenesis of ARID1A-depleted NSCLC cells. Taken together, PLAU serves as a target gene of ARID1A and promotes NSCLC growth, survival, and cisplatin resistance by stabilizing TM4SF1 . Targeting TM4SF1 may be a promising therapeutic strategy for ARID1A-mutated NSCLC.  \nKeywords ARID1A, Chemoresistance, Growth, Lung cancer, PLAU  \n†Yuanliang Zheng and Lixiang Zhang contributed equally to this work.  \n*Correspondence: Risheng Huang [hrs9900@wmu.edu.cn](hrs9900@wmu.edu.cn)[ ](hrs9900@wmu.edu.cn)Hongli Liao [hongliliao1@163.com](hongliliao1@163.com)  \n1Department of Thoracic Surgery, The Dingli Clinical College of Wenzhou Medical University, Wenzhou Central Hospital, The Second Affiliated Hospital of Shanghai University, Wenzhou, China  \n2Department of Central Lab, The Dingli Clinical College of Wenzhou Medical University, Wenzhou Central Hospital, The Second Affiliated Hospital of Shanghai University, Wenzhou, China  \n3Department of Hematology and Chemotherapy, The Dingli Clinical College of Wenzhou Medical University, Wenzhou Central Hospital, The Second Affiliated Hospital of Shanghai University, Wenzhou, China 4Department of Pathology, The Dingli Clinical College of Wenzhou Medical University, Wenzhou Central Hospital, The Second Affiliated Hospital of Shanghai University, Wenzhou, China  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ([http://creativecommons.org/publicdo","cbCaieUn8aNg2yKb","https://ap.wps.com/l/cbCaieUn8aNg2yKb","pdf",7489797,14,"English","# Abstract\n# Introduction\n## ARID1A and SWI/SNF background\n## NSCLC resistance and need for mechanisms","[{\"question\":\"How does ARID1A loss influence NSCLC progression and therapy response?\",\"answer\":\"ARID1A loss contributes to aggressive progression and is associated with drug resistance in NSCLC. The study focuses on identifying downstream genes that mediate these effects.\"},{\"question\":\"What role does PLAU play in ARID1A-depleted NSCLC?\",\"answer\":\"PLAU is induced upon ARID1A depletion. Overexpressing PLAU promotes NSCLC cell growth and colony formation, enhances survival, and increases cisplatin resistance.\"},{\"question\":\"How is the PLAU–TM4SF1–Akt axis connected to chemoresistance?\",\"answer\":\"PLAU interacts with TM4SF1 to activate Akt signaling. TM4SF1 overexpression mimics PLAU effects, while TM4SF1 knockdown or anti-TM4SF1 antibody reduces growth and cisplatin resistance.\"}]","PLAU promotes growth and attenuates cisplatin chemosensitivity in ARID1A-depleted non-small cell lung cancer through interaction with TM4SF1 | PDF",1790025868,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/888e3764d739b65973062aba586f7465.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8aee9053269eb288bb8fc4da90bbf860.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cbcdd6289e9136615f3304747209a3d3.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5c6e980c72c8368eee2a57e17d0d4de4.webp",980,1306]